Leveraging high-purity recombinant MOG protein provided by AtaGenix, this study shows that brain-border autoreactive B cells initiate and amplify CNS autoimmunity in EAE. Intracisterna magna delivery selectively manipulated leptomeningeal B cells, revealing MHC II–dependent cognate interactions with encephalitogenic T cells that boost GM-CSF, recruit neutrophils, and activate endothelium before symptoms. These events form a local inflammatory loop that accelerates onset. Selective depletion of brain-localized B cells attenuated relapse without systemic B-cell ablation, establishing meningeal autoreactive B cells as key initiators of neuroinflammation and tractable therapeutic targets in relapsing multiple sclerosis.

Patatin is a potato glycoprotein with emulsifying and antioxidant properties but limited by low expression and short-chain bias. With AtaGenix support, recombinant Patatin was expressed in Pichia pastoris (121 mg/L). The D286A mutant showed 3.2-fold higher long-chain activity, improved stability (+5.4 °C), and preserved structure. This AtaGenix-enabled work offers a scalable platform for Patatin engineering with applications in functional lipids, food biotechnology, and green biocatalysis.

AtaGenix offers professional mammalian cell protein expression services, specializing in foundational research, drug development, and diagnostic reagent production. We excel in efficiently producing high-quality recombinant proteins with natural post-translational modifications.

• High Expression Efficiency: Utilizing optimized expression systems, we achieve efficient protein production, catering to diverse production scales.
• Natural Post-Translational Modifications: Mammalian cell systems enable natural post-translational modifications such as glycosylation and phosphorylation, preserving the biological activity of the proteins.
• Flexible Customization Services: Tailored to meet specific client requirements, we offer a wide range of expression vectors, tags, and purification strategies to ensure the final produc

AtaGenix offers the XtenCHO™ High-Density Transient Transfection Expression System, specifically designed for efficient protein and antibody production. This system features high expression levels, excellent cell viability, and cost-effectiveness, making it suitable for large-scale antibody and protein production needs across research and industrial applications. The XtenCHO™ cells are genetically optimized to enable efficient and stable antibody expression, providing reliable support for high-throughput experiments and industrial-scale production.

AtaGenix provides professional prokaryotic protein expression services, tailored for basic research and protein engineering. The service includes project evaluation, vector construction, protein purification, and quality testing. The prokaryotic system offers advantages such as high yield and cost efficiency. This service is applicable to enzyme engineering, drug target research, and antibody development, supporting scientific research efforts.

AtaGenix, a leader in biotechnology, has pioneered the development of the ENO1 monoclonal antibody (ENO1mAb) using advanced hybridoma technology to target α-enolase (ENO1), a key enzyme in cervical cancer progression. Expressed in insect cells and delivered via proprietary folic acid-conjugated PLGA nanoparticles, ENO1mAb effectively inhibits tumor invasion, proliferation, and clone formation by blocking ENO1's glycolytic and plasminogen activation roles. In vitro studies demonstrate significant reductions in lactic acid and pyruvate levels, showcasing AtaGenix's innovative approach to transforming cervical cancer treatment.